← Leaderboards
Marc Ladanyi
Sloan-Kettering Institute For Cancer Res
$28,443,479
Attributed
$38,477,284
Total exposure
21
Grants
14
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $6.3M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$55,509,895 · 22
By mechanism
P01$31,771,382 · 12
U24$16,614,816 · 2
P50$4,685,939 · 6
R01$1,400,950 · 1
U01$1,036,808 · 1
Top collaborators
- Mark G Kris15 shared
- Chris Sander8 shared
- Scott W Lowe5 shared
- Joan Massague5 shared
- William Pao5 shared
- Neal Rosen5 shared
- Ronglai Shen5 shared
- Andrea Ventura2 shared
Most similar at Sloan-Kettering Institute For Cancer Res
Same institution · by research overlap
- Joan Massague$31,163,003
- Nai-Kong V Cheung$9,578,208
- Irene Y Cheung$317,000
Others in their field
Top investigators on “Base”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$613,567,095
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Larry Arthur$521,411,998
- Leonard Freedman · Leidos Biomedical Research, Inc.$515,995,429
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$507,042,060
Research focus
BaseMalignant NeoplasmsTumorProgramsMalignant Neoplasm Of LungGenesResearch PersonnelLung CarcinomaResponseMutationProteinsMolecularResearch Project GrantsPreventGenomicsSamplingMemorial Sloan-Kettering Cancer CenterLungMolecular ProfilingPathway InteractionsResistanceNeoplasm MetastasisLung AdenocarcinomaCell Line
Grant awards (112)
Desmoplastic small round cell tumor: harnessing new insights and new models$508,904
U01 · FY2025 · CA · contact PI
Project 3: Identifying Targetable Epigenetic and Immuno-Oncologic Vulnerabilities in Synovial Sarcoma$433,378
P50 · FY2025 · CA · contact PI
Developmental Research Program$88,000
P50 · FY2025 · CA · contact PI
Desmoplastic small round cell tumor: harnessing new insights and new models$527,904
U01 · FY2024 · CA · contact PI
Project 3: Identifying Targetable Epigenetic and Immuno-Oncologic Vulnerabilities in Synovial Sarcoma$436,396
P50 · FY2024 · CA · contact PI
Developmental Research Program$84,454
P50 · FY2024 · CA · contact PI
Epigenetic and Genetic Vulnerabilities in Synovial Sarcoma$206,686
P50 · FY2023 · CA · contact PI
Targets for Therapy for Carcinomas of the Lung$1,671,655
P01 · FY2022 · CA
Epigenetic and Genetic Vulnerabilities in Synovial Sarcoma$344,657
P50 · FY2022 · CA · contact PI
Core 2: Molecular Profiling and Pathology$133,591
P01 · FY2022 · CA · contact PI
Developmental Research Program$69,844
P50 · FY2022 · CA · contact PI
Targets for Therapy for Carcinomas of the Lung$1,705,771
P01 · FY2021 · CA
Epigenetic and Genetic Vulnerabilities in Synovial Sarcoma$344,657
P50 · FY2021 · CA · contact PI
Core 2: Molecular Profiling and Pathology$136,318
P01 · FY2021 · CA · contact PI
Developmental Research Program$69,845
P50 · FY2021 · CA · contact PI
Targets for Therapy for Carcinomas of the Lung$1,705,771
P01 · FY2020 · CA
Epigenetic and Genetic Vulnerabilities in Synovial Sarcoma$349,035
P50 · FY2020 · CA · contact PI
Core 2: Molecular Profiling and Pathology$136,318
P01 · FY2020 · CA · contact PI
Developmental Research Program$74,222
P50 · FY2020 · CA · contact PI
Targets for Therapy for Carcinomas of the Lung$1,654,596
P01 · FY2019 · CA
Epigenetic and Genetic Vulnerabilities in Synovial Sarcoma$335,415
P50 · FY2019 · CA · contact PI
Core 2: Molecular Profiling and Pathology$267,807
P01 · FY2019 · CA · contact PI
Developmental Research Program$79,840
P50 · FY2019 · CA · contact PI
Targets for Therapy for Carcinomas of the Lung$1,725,669
P01 · FY2018 · CA
Epigenetic and Genetic Vulnerabilities in Synovial Sarcoma$360,663
P50 · FY2018 · CA · contact PI
Core 2: Molecular Profiling and Pathology$276,090
P01 · FY2018 · CA · contact PI
Developmental Research Program$85,850
P50 · FY2018 · CA · contact PI
Targets for Therapy for Carcinomas of the Lung$1,736,914
P01 · FY2016 · CA
MSKCC Center for Translational Cancer Genomic Analysis$500,000
U24 · FY2016 · CA
Mechanisms and Modulators of Sensitivity and Resistance to EGFR Inhibitors in Lu$390,070
P01 · FY2016 · CA
Lung Cancer Drivers and Dependencies as Therapeutic Targets$365,049
P01 · FY2016 · CA
Mediators of Lung Adenocarcinoma Metastasis$253,248
P01 · FY2016 · CA
Targeting the ERK Pathway in KRAS-and BRAF-Driven Lung Cancers$248,430
P01 · FY2016 · CA
Molecular Profiling and Pathology$212,444
P01 · FY2016 · CA · contact PI
Biostatistics and Bioinformatics$140,456
P01 · FY2016 · CA
Administration Core$127,217
P01 · FY2016 · CA
Targets for Therapy for Carcinomas of the Lung$1,736,914
P01 · FY2015 · CA
Mechanisms and Modulators of Sensitivity and Resistance to EGFR Inhibitors in Lu$390,070
P01 · FY2015 · CA
Lung Cancer Drivers and Dependencies as Therapeutic Targets$365,049
P01 · FY2015 · CA
Mediators of Lung Adenocarcinoma Metastasis$253,248
P01 · FY2015 · CA
Targeting the ERK Pathway in KRAS-and BRAF-Driven Lung Cancers$248,430
P01 · FY2015 · CA
Molecular Profiling and Pathology$212,444
P01 · FY2015 · CA · contact PI
Biostatistics and Bioinformatics$140,456
P01 · FY2015 · CA
Administration Core$127,217
P01 · FY2015 · CA
Targets for Therapy for Carcinomas of the Lung$1,684,807
P01 · FY2014 · CA
MSKCC Center for Translational Cancer Genomic Analysis$1,250,000
U24 · FY2014 · CA
Mechanisms and Modulators of Sensitivity and Resistance to EGFR Inhibitors in Lu$382,626
P01 · FY2014 · CA
Lung Cancer Drivers and Dependencies as Therapeutic Targets$357,605
P01 · FY2014 · CA
Mediators of Lung Adenocarcinoma Metastasis$245,804
P01 · FY2014 · CA
Targeting the ERK Pathway in KRAS-and BRAF-Driven Lung Cancers$240,985
P01 · FY2014 · CA
P4 Elucidating SYT-SSX-depend histone code alterations to guide targeted epigenet$216,569
P50 · FY2014 · CA · contact PI
Molecular Profiling and Pathology$205,000
P01 · FY2014 · CA · contact PI
Biostatistics and Bioinformatics$133,013
P01 · FY2014 · CA
Administration Core$119,774
P01 · FY2014 · CA
Developmental Research Program$44,152
P50 · FY2014 · CA · contact PI
MSKCC Center for Translational Cancer Genomic Analysis$2,782,392
U24 · FY2013 · CA
Targets for Therapy for Carcinomas of the Lung$1,632,700
P01 · FY2013 · CA
Mechanisms and Modulators of Sensitivity and Resistance to EGFR Inhibitors in Lu$366,666
P01 · FY2013 · CA
Lung Cancer Drivers and Dependencies as Therapeutic Targets$343,146
P01 · FY2013 · CA
Mediators of Lung Adenocarcinoma Metastasis$238,055
P01 · FY2013 · CA
Targeting the ERK Pathway in KRAS-and BRAF-Driven Lung Cancers$233,526
P01 · FY2013 · CA
P4 Elucidating SYT-SSX-depend histone code alterations to guide targeted epigenet$214,648
P50 · FY2013 · CA · contact PI
Molecular Profiling and Pathology$199,697
P01 · FY2013 · CA · contact PI
Biostatistics and Bioinformatics$132,027
P01 · FY2013 · CA
Administration$119,583
P01 · FY2013 · CA
Developmental Research Program$43,759
P50 · FY2013 · CA · contact PI
Targets for Therapy for Carcinomas of the Lung$1,777,814
P01 · FY2012 · CA
MSKCC Center for Translational Cancer Genomic Analysis$1,582,181
U24 · FY2012 · CA
Mechanisms and Modulators of Sensitivity and Resistance to EGFR Inhibitors in Lu$399,448
P01 · FY2012 · CA
Lung Cancer Drivers and Dependencies as Therapeutic Targets$372,966
P01 · FY2012 · CA
Mediators of Lung Adenocarcinoma Metastasis$259,338
P01 · FY2012 · CA
Targeting the ERK Pathway in KRAS-and BRAF-Driven Lung Cancers$254,404
P01 · FY2012 · CA
P4 Elucidating SYT-SSX-depend histone code alterations to guide targeted epigenet$228,571
P50 · FY2012 · CA · contact PI
Molecular Profiling and Pathology$217,552
P01 · FY2012 · CA · contact PI
Biostatistics and Bioinformatics$143,832
P01 · FY2012 · CA
Administration$130,274
P01 · FY2012 · CA
Developmental Research Program$46,673
P50 · FY2012 · CA · contact PI
MSKCC Center for Translational Cancer Genomic Analysis$1,540,730
U24 · FY2011 · CA
Molecular Profiling and Pathology$350,207
P01 · FY2011 · CA · contact PI
P4 Elucidating SYT-SSX-depend histone code alterations to guide targeted epigenet$216,180
P50 · FY2011 · CA · contact PI
Developmental Research Program$44,215
P50 · FY2011 · CA · contact PI
MSKCC Center for Translational Cancer Genomic Analysis$1,617,563
U24 · FY2010 · CA
MSKCC Center for Translational Cancer Genomic Analysis$785,924
U24 · FY2010 · CA
Molecular Pathology of Synovial Sarcoma$368,408
P01 · FY2010 · CA · contact PI
Molecular Profiling and Pathology$365,233
P01 · FY2010 · CA · contact PI
P4 Elucidating SYT-SSX-depend histone code alterations to guide targeted epigenet$222,685
P50 · FY2010 · CA · contact PI
Developmental Research Program$45,545
P50 · FY2010 · CA · contact PI
MSKCC Center for Translational Cancer Genomic Analysis$1,450,000
U24 · FY2009 · CA
The TCGA Cancer Genome Characterization Center at MSKCC$532,000
U24 · FY2009 · CA · contact PI
Molecular Profiling and Pathology$421,488
P01 · FY2009 · CA · contact PI
Molecular Pathology of Synovial Sarcoma$363,169
P01 · FY2009 · CA · contact PI
Project 2$256,184
P01 · FY2009 · CA · contact PI
The TCGA Cancer Genome Characterization Center at MSKCC$1,503,065
U24 · FY2008 · CA · contact PI
Molecular Profiling and Pathology$357,813
P01 · FY2008 · CA · contact PI
Molecular Pathology of Synovial Sarcoma$354,581
P01 · FY2008 · CA · contact PI
Project 2$250,451
P01 · FY2008 · CA · contact PI
The TCGA Cancer Genome Characterization Center at MSKCC$1,488,605
U24 · FY2007 · CA · contact PI
Molecular Pathology of Synovial Sarcoma$353,102
P01 · FY2007 · CA · contact PI
Molecular Profiling and Pathology$310,882
P01 · FY2007 · CA · contact PI
Project 2$289,911
P01 · FY2007 · CA · contact PI
The TCGA Cancer Genome Characterization Center at MSKCC$1,582,356
U24 · FY2006 · CA · contact PI
ASPL TFE3 fusion in human cancers$275,500
R01 · FY2006 · CA · contact PI
Project 2$167,489
P01 · FY2006 · CA · contact PI
Molecular Pathology of Synovial Sarcoma$158,481
P01 · FY2006 · CA · contact PI
ASPL TFE3 fusion in human cancers$282,130
R01 · FY2005 · CA
Project 2$160,206
P01 · FY2005 · CA
ASPL TFE3 fusion in human cancers$282,130
R01 · FY2004 · CA
ASPL TFE3 fusion in human cancers$282,130
R01 · FY2003 · CA
ASPL TFE3 fusion in human cancers$279,060
R01 · FY2002 · CA
MOLECULAR PATHOLOGY OF SYNOVIAL SARCOMA$230,631
P01 · FY2002 · CA
MOLECULAR PATHOLOGY OF SYNOVIAL SARCOMA$230,631
P01 · FY2001 · CA
MOLECULAR PATHOLOGY OF SYNOVIAL SARCOMA$230,631
P01 · FY2000 · CA